A phase III study of PP405 in men and women experiencing hair loss
Latest Information Update: 23 Jun 2025
At a glance
- Drugs PP 405 (Primary)
- Indications Alopecia
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 23 Jun 2025 New trial record
- 17 Jun 2025 According to Pelage Pharmaceuticals media release, the company expects to initiate Phase 3 studies in 2026.